- Home
- ECO vs XERS Comparison
ECO vs XERS Comparison
Compare ECO & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECO | XERS |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ECO | XERS |
|---|---|---|
| Price | $85.31 | $16.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $69.67 | $17.29 |
| AVG Volume (30 Days) | 888.2K | ★ 3.1M |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | ★ 11.14% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $153.32 | $37.58 |
| Revenue Next Year | N/A | $31.16 |
| P/E Ratio | $18.60 | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $31.75 | $5.25 |
| 52 Week High | $102.56 | $16.57 |
Technical Indicators
Market Signals| Indicator | ECO | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 46.80 | 84.86 |
| Support Level | $47.47 | $5.90 |
| Resistance Level | $87.31 | N/A |
| Average True Range (ATR) | 4.23 | 0.67 |
| MACD | -1.90 | 0.60 |
| Stochastic Oscillator | 29.09 | 97.29 |
Price Performance
Historical ComparisonAbout ECO Okeanis Eco Tankers Corp.
Okeanis Eco Tankers Corp is an international owner and operator of a fleet of tanker vessels used for the transportation of crude oil. Its fleet consists of modern Suezmax and VLCC tankers that are designed in accordance with eco-efficiency standards, including features such as reduced fuel consumption, exhaust gas cleaning systems, and ballast water treatment systems. All of the company's revenue is derived from a single segment, the crude oil tanker segment. Geographically, the maximum revenue is generated from Europe, and the rest from Asia, North America, and South America.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.